Class / Patent application number | Description | Number of patent applications / Date published |
514150500 | Surfactant protein (e.g., SP-A, SP-B, etc.) or derivative affecting or utilizing | 14 |
20100273712 | SURFACTANT USAGE IN LUNG TRANSPLANTATION AND METHODS THEREOF - The present invention is directed to the use of pulmonary surfactants, and particularly pulmonary surfactants containing hydrophobic surfactant-associated proteins B, C or both (i.e., surfactants such as calfactant (Infasurf®), to treat PGD and other adverse effects of lung transplantation. | 10-28-2010 |
20110130333 | THERAPEUTIC COMBINATION COMPRISING A PULMONARY SURFACTANT AND A STEROID - Administration of a modified natural surfactant in combination with a corticosteroid is effective for the prevention of bronchopulmonary dysplasia (BPD) and lowers the markers of pulmonary oxidative stress. | 06-02-2011 |
20120010145 | Methods and Compositions for Delivery of Medicaments to the Lungs - The disclosure provides a drug composition formulated for inhalation comprising a conjugate of a surface active agent and a pulmonary active drug. The surface active agent has an affinity for the human alveolar/gas interface and comprises at least a portion of a mammalian lung surfactant of a mimic thereof. The disclosure also provides a method of treating a subject suffering from or at risk of suffering from a lung disease comprising administering to the subject a conjugate comprising a drug for lung treatment and a surface active agent by inhalation in an amount effective to induce a drug effect in the lungs. | 01-12-2012 |
20120142596 | AGENT FOR STIMULATING MOBILIZATION OF ENDOTHELIAL PROGENITOR CELLS - The present invention provides a composition for stimulating the mobilization of endothelial precursor cells, which comprises substance-P (SP). Substance-P according to the invention exhibits an activity of stimulating the mobilization of endothelial precursor cells from the bone marrow, thereby stimulating vasculogenesis. Thus, substance-P exhibits excellent effects on the prevention or treatment of diseases, including myocardial infarction, angina, ischemic stroke, cerebrovascular dementia, cerebral infarction, sequelae of cerebral injury, spinal cord injury, sequelae of spinal nerve injury, degenerative diseases, sequelae of cerebral infarction, peripheral nerve disorders, presbyopia, degenerative hearing loss, sequelae of brain surgery, and diabetic ulcer, which are accompanied by ischemic vascular injury or traumatic vascular injury. | 06-07-2012 |
20120220531 | SURFACTANT PROTEIN D FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH LUNG INJURY - Surfactant protein D (SP-D) is a member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. Described herein are methods and compositions for the treatment of disorders associated with lung injury, including methods and compositions for the treatment of bronchopulmonary disorder (BPD). | 08-30-2012 |
20120258918 | Polypeptoid pulmonary surfactants - The present invention provides spreading agents based on sequence-specific oligomers comprising a peptoid, a peptide-peptoid chimera, a retropeptoid or a retro(peptoid-peptide) chimera, and methods for using the same, including for the treatment of respiratory distress of the lungs. The spreading agents are sequence-specific oligomers, including retrosequence-specific oligomers, based on a peptide backbone, that are designed as analogs of surfactant protein-B or surfactant protein-C. | 10-11-2012 |
20130065833 | ALKYLATED SP-B PEPTOID COMPOUNDS AND RELATED LUNG SURFACTANT COMPOSITIONS - SP-B peptoid compounds, lung surfactant compositions and related surfactant replacement therapies. Such SP-B peptoids can mimic lung surfactant protein B, and can be used in conjunction with biomimetic SP-C compounds over a range of lung surfactant compositions. | 03-14-2013 |
20130109627 | ALKYLATED SP-C PEPTOID COMPOUNDS AND RELATED SURFACTANT COMPOSITIONS | 05-02-2013 |
20140135268 | SURFACTANT PROTEIN D FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH LUNG INJURY - Surfactant protein D (SP-D) is a member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. Described herein are methods and compositions for the treatment of disorders associated with lung injury, including methods and compositions for the treatment of bronchopulmonary disorder (BPD). | 05-15-2014 |
20140243272 | COMPOUND AND METHOD FOR TREATMENT OF ALZHEIMER'S DISEASE - An isolated protein selected from the group consisting of (i) proteins comprising an amino acid sequence having at least 70% identity to the C-terminal domain of lung surfactant protein C precursor (CTproSP-C, “CTC”) from a mammal; and (ii) proteins comprising an amino acid sequence having at least 70% identity to the Brichos domain of CTproSP-C from a mammal, is disclosed for treatment of Alzheimer's disease in a mammal, including man. | 08-28-2014 |
20140378383 | METHODS AND COMPOSITIONS FOR DELIVERY OF MEDICAMENTS TO THE LUNGS - The disclosure provides a drug composition formulated for inhalation comprising a conjugate of a surface active agent and a pulmonary active drug. The surface active agent has an affinity for the human alveolar/gas interface and comprises at least a portion of a mammalian lung surfactant of a mimic thereof. The disclosure also provides a method of treating a subject suffering from or at risk of suffering from a lung disease comprising administering to the subject a conjugate comprising a drug for lung treatment and a surface active agent by inhalation in an amount effective to induce a drug effect in the lungs. | 12-25-2014 |
20150297524 | LYOPHILIZATION OF SYNTHETIC LIPOSOMAL PULMONARY SURFACTANT - Lyophilized pulmonary surfactants having an increased specific surface area and porosity are described. Methods of making the lyophilized pulmonary surfactants are also described. | 10-22-2015 |
20160115537 | PROGNOSIS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND TREAMENT FOR COPD - The preset invention relates to a method for predicting the disease outcome and/or prognosis of chronic obstructive pulmonary disease (COPD) using a variant of surfactant protein D (SP-D) as a biomarker, which is the G-G-C-C-A haplotype of SP-D. | 04-28-2016 |
20160375106 | DILUTE SURFACTANT OR ISOLATED SURFACTANT PROTEIN SOLUTION FOR THE REDUCTION OF SURFACE TENSION IN THE LUNG - In permeability lung edema, cardiogenic lung edema or neonatal respiratory distress, there is heterogeneous liquid distribution throughout the lungs. The excess alveolar liquid reduces gas exchange. Mechanical ventilation is used to improve gas exchange. In the presence of heterogeneous liquid distribution, there are surface tension-dependent stress concentrations in septa separating aerated from flooded alveoli. Mechanical ventilation, by inflating the lung above normal volumes, thus increasing surface tension above normal, exacerbates the stress concentrations and consequently injures, or exacerbates pre-existing injury of, the alveolar-capillary barrier. Any means of lowering surface tension should lessen ventilation injury of the lung. In the present invention, dilute exogenous surfactant solution or surfactant protein C solution interacts with albumin to lower surface tension, likely through effective promotion of surfactant lipid adsorption. Dilute surfactant or SP-C solution could be administered via either the trachea or the vasculature. Either solution could be delivered in the absence or presence of albumin or alternative facilitating solute, to lower surface tension and lessen ventilation injury of the heterogeneously flooded lung. | 12-29-2016 |